wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37604501-6049CBF3-C8D2-4121-9BFE-316E3434441B
Q37604501-6049CBF3-C8D2-4121-9BFE-316E3434441B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37604501-6049CBF3-C8D2-4121-9BFE-316E3434441B
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
P2860
Q37604501-6049CBF3-C8D2-4121-9BFE-316E3434441B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37604501-6049CBF3-C8D2-4121-9BFE-316E3434441B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f30388c170bc2d9f5f8d6741cba5d47e45c86182
P2860
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.